Compare FHB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHB | IDYA |
|---|---|---|
| Founded | 1858 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2016 | 2019 |
| Metric | FHB | IDYA |
|---|---|---|
| Price | $27.19 | $33.89 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $26.43 | ★ $52.86 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | 22.91 | ★ 61.90 |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $880,788,000.00 | $218,710,000.00 |
| Revenue This Year | $7.00 | N/A |
| Revenue Next Year | $3.56 | $201.05 |
| P/E Ratio | $12.19 | ★ N/A |
| Revenue Growth | 8.94 | ★ 3024.43 |
| 52 Week Low | $22.43 | $16.82 |
| 52 Week High | $28.35 | $39.28 |
| Indicator | FHB | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 69.45 | 56.65 |
| Support Level | $25.95 | $32.85 |
| Resistance Level | $27.47 | $34.76 |
| Average True Range (ATR) | 0.55 | 2.07 |
| MACD | 0.19 | 0.28 |
| Stochastic Oscillator | 92.15 | 45.01 |
First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.